Vitaspring Biomedical Co. Ltd 8-K, filed Aug 11, 2021
Vitaspring Biomedical Co. Ltd. (VSBC)
About this 8-K
Vitaspring Biomedical Co. Ltd filed this 8-K on August 11, 2021, reporting on events of August 7, 2020.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) | ||
|
| ||||
| (Address of Principal Executive Offices) (Zip Code) | ||||
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
____________________________________________________________________________________
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
Effective August 7, 2020, Chu Pao-Chi Chairman of the Board of Directors, and Chief Executive Officer of the Company, resigned his position as CEO and current secretary of the Company, Kao Cheng-Hsiang, was appointed CEO and retains his position as Secretary.
The remaining officers of the Company, Lin Jer-Li Chief Technical Officer of the Company and Chen Yen Xun Technical Vice-President of the Company, remain the same.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| VITASPRING BIOMEDICAL CO. LTD. | ||
| August 11, 2021 |
By: /s/ Kao Cheng-Hsiang
|